These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22241219)

  • 1. Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype.
    Joseph J; Shiozawa Y; Jung Y; Kim JK; Pedersen E; Mishra A; Zalucha JL; Wang J; Keller ET; Pienta KJ; Taichman RS
    Mol Cancer Res; 2012 Mar; 10(3):282-92. PubMed ID: 22241219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
    Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
    J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
    Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
    PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
    Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
    PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
    Hall CL; Bafico A; Dai J; Aaronson SA; Keller ET
    Cancer Res; 2005 Sep; 65(17):7554-60. PubMed ID: 16140917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice.
    Schepers K; Hsiao EC; Garg T; Scott MJ; Passegué E
    Blood; 2012 Oct; 120(17):3425-35. PubMed ID: 22859604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche.
    Jung Y; Song J; Shiozawa Y; Wang J; Wang Z; Williams B; Havens A; Schneider A; Ge C; Franceschi RT; McCauley LK; Krebsbach PH; Taichman RS
    Stem Cells; 2008 Aug; 26(8):2042-51. PubMed ID: 18499897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Morrissey C; Lai JS; Brown LG; Wang YC; Roudier MP; Coleman IM; Gulati R; Vakar-Lopez F; True LD; Corey E; Nelson PS; Vessella RL
    Prostate; 2010 Mar; 70(4):412-24. PubMed ID: 19866469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roundabout 4 is expressed on hematopoietic stem cells and potentially involved in the niche-mediated regulation of the side population phenotype.
    Shibata F; Goto-Koshino Y; Morikawa Y; Komori T; Ito M; Fukuchi Y; Houchins JP; Tsang M; Li DY; Kitamura T; Nakajima H
    Stem Cells; 2009 Jan; 27(1):183-90. PubMed ID: 18927479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional localization within the bone marrow influences the functional capacity of human HSCs.
    Guezguez B; Campbell CJ; Boyd AL; Karanu F; Casado FL; Di Cresce C; Collins TJ; Shapovalova Z; Xenocostas A; Bhatia M
    Cell Stem Cell; 2013 Aug; 13(2):175-89. PubMed ID: 23910084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer.
    Sung SY; Liao CH; Wu HP; Hsiao WC; Wu IH; Jinpu ; Yu ; Lin SH; Hsieh CL
    PLoS One; 2013; 8(8):e71637. PubMed ID: 23977098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
    Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
    Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
    Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.
    Shiozawa Y; Pedersen EA; Havens AM; Jung Y; Mishra A; Joseph J; Kim JK; Patel LR; Ying C; Ziegler AM; Pienta MJ; Song J; Wang J; Loberg RD; Krebsbach PH; Pienta KJ; Taichman RS
    J Clin Invest; 2011 Apr; 121(4):1298-312. PubMed ID: 21436587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.
    Li X; Sterling JA; Fan KH; Vessella RL; Shyr Y; Hayward SW; Matrisian LM; Bhowmick NA
    Mol Cancer Res; 2012 Apr; 10(4):494-503. PubMed ID: 22290877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.